GERON CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.56 USD | -0.56% |
|
-4.56% | +68.72% |
| Mar. 19 | Geron Prices $150 Million Offering of Shares, Pre-Funded Warrants | MT |
| Mar. 15 | Sector Update: Health Care Stocks Ease Late Afternoon | MT |
Presenter SpeechUnknown Analyst (Analysts)Okay. Welcome to our 2022 Morgan Stanley Healthcare ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Calendar
2024-05-05
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
3.56
USD
Average target price
5.083
USD
Spread / Average Target
+42.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +68.72% | 2.11B | |
| -2.26% | 104B | |
| +1.41% | 97.42B | |
| +0.79% | 22.2B | |
| -17.84% | 21.23B | |
| -11.11% | 18.33B | |
| -42.83% | 16.35B | |
| -17.63% | 15.06B | |
| +4.55% | 13.98B | |
| +32.11% | 11.66B |
- Stock Market
- Equities
- GERN Stock
- News Geron Corporation
- Transcript : Geron Corporation Presents at Morgan Stanley 20th Annual Global Healthcare Conference, Sep-12-2022 05
